lamotrigine has been researched along with Depression, Involutional in 42 studies
Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "83 weeks) in patients with unipolar depression (studies=4, n=187; monotherapy vs lithium=1, augmentation of antidepressants vs placebo=3) or bipolar depression (studies=14, n=1965; monotherapy vs placebo=5, monotherapy vs lithium or olanzapine+fluoxetine=2, augmentation of antidepressants vs placebo=1, augmentation of mood stabilizers vs placebo=3, augmentation of mood stabilizers vs trancylpromine, citalopram, or inositol=3) were meta-analyzed." | 8.93 | Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. ( Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016) |
| "Hemophagocytic lymphohistiocytosis is a rare hematological syndrome characterized by excessive and uncontrolled activation of the immune system." | 5.51 | Lamotrigine-induced hemophagocytic lymphohistiocytosis with Takotsubo cardiomyopathy: a case report. ( Martinez, JA; Shen, JP; Zhou, JY, 2019) |
| "The anti-epileptic drug lamotrigine (LTG) has been widely used to treat various neurological disorders, including epilepsy and bipolar disorder." | 5.41 | Understanding Lamotrigine's Role in the CNS and Possible Future Evolution. ( Costa, B; Vale, N, 2023) |
| "83 weeks) in patients with unipolar depression (studies=4, n=187; monotherapy vs lithium=1, augmentation of antidepressants vs placebo=3) or bipolar depression (studies=14, n=1965; monotherapy vs placebo=5, monotherapy vs lithium or olanzapine+fluoxetine=2, augmentation of antidepressants vs placebo=1, augmentation of mood stabilizers vs placebo=3, augmentation of mood stabilizers vs trancylpromine, citalopram, or inositol=3) were meta-analyzed." | 4.93 | Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. ( Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016) |
| "A 40-year old woman with a history of acute psychotic symptoms developed agranulocytosis and neutropenia after starting therapy that included lamotrigine, mirtazapine, quetiapine, and venlafaxine." | 3.78 | Fatal agranulocytosis associated with psychotropic medication use. ( Al-Najjar, T; Ali, BA; Nazer, LH; Shankar, G, 2012) |
| "Most studies suggested that LAM was safe and effective in pediatric patients with mood disorders." | 3.01 | Efficacy and safety of lamotrigine in pediatric mood disorders: A systematic review. ( Ahern, K; Athreya, AP; Croarkin, PE; Garzon, J; Hassett, LC; Kumar, R; Ozger, C; Oztosun, C; Saliba, M; Singh, B; Vande Voort, JL; Yuruk, D, 2023) |
| "The diagnoses were major depressive disorder (n = 15), bipolar I disorder (n = 6), and bipolar II disorder (n = 16)." | 2.82 | Prediction of an Optimal Dose of Lamotrigine for Augmentation Therapy in Treatment-Resistant Depressive Disorder From Plasma Lamotrigine Concentration at Week 2. ( Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Suzuki, T, 2016) |
| "Lamotrigine was found effective and safe as add-on treatment to lithium in the acute treatment of bipolar depression." | 2.74 | Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. ( Blom, MB; de Keyzer, HJ; Hartong, EG; Luteijn, ML; Mulder, PG; Nolen, WA; Notten, PJ; Timmermans, MA; van der Loos, ML; Vergouwen, AC; Vieta, E, 2009) |
| "Lamotrigine-augmentation was well tolerated." | 2.73 | Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. ( Anghelescu, IG; Schindler, F, 2007) |
| "Lamotrigine has demonstrated efficacy for the acute treatment of depression in bipolar I patients in a placebo-controlled, monotherapy study." | 2.71 | A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression. ( Ascher, J; Cookson, J; Greene, P; Huffman, RF; McElroy, SL; Suppes, T; Zarate, CA, 2004) |
| "Although mania defines bipolar I disorder, depressive episodes and symptoms dominate the longitudinal course of, and disproportionately account for morbidity and mortality in, bipolar disorders." | 2.66 | Bipolar disorders. ( Berk, M; Brietzke, E; Goldstein, BI; Kessing, LV; López-Jaramillo, C; Majeed, A; Malhi, GS; Mansur, RB; McIntyre, RS; Nierenberg, AA; Rosenblat, JD; Vieta, E; Vinberg, M; Young, AH, 2020) |
| " This article explores potential pharmacokinetic and pharmacodynamic drug interactions of relevance to the use of ketamine in depression." | 2.55 | Ketamine for Depression, 5: Potential Pharmacokinetic and Pharmacodynamic Drug Interactions. ( Andrade, C, 2017) |
| "Ms F's hereditary coproporphyria was diagnosed 9 years before the current admission." | 2.50 | Lamotrigine in the treatment of psychotic depression associated with hereditary coproporphyria -- case report and a brief review of the literature. ( Gazdag, G; Kassai-Farkas, Á; Makkos, Z; Pusztai, Á; Takács, R; Ungvári, GS, 2014) |
| "There were no cases of toxic epidermal necrolysis in any setting." | 2.41 | Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. ( Bowden, CL; Calabrese, JR; Frye, MA; Goldberg, JF; Goodwin, FK; Kusumakar, V; Sachs, GS; Shelton, MD; Sullivan, JR; Suppes, T, 2002) |
| "We present a case of a patient with major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) who was diagnosed with PGAD shortly after she was started on lamotrigine for mood stabilization." | 1.91 | Lamotrigine-Induced Persistent Genital Arousal Disorder and a Potential Treatment. ( Artounian, K; Petty, A; Shah, N; Suwarno, S; Vedula, S, 2023) |
| "The diagnoses were major depressive disorder (n = 39), bipolar I disorder (n = 10), and bipolar II disorder (n = 35)." | 1.56 | A High Plasma Lamotrigine Concentration at Week 2 as a Risk Factor for Lamotrigine-Related Rash. ( Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Suzuki, T, 2020) |
| "Hemophagocytic lymphohistiocytosis is a rare hematological syndrome characterized by excessive and uncontrolled activation of the immune system." | 1.51 | Lamotrigine-induced hemophagocytic lymphohistiocytosis with Takotsubo cardiomyopathy: a case report. ( Martinez, JA; Shen, JP; Zhou, JY, 2019) |
| "The diagnoses were major depressive disorder (n = 19), bipolar I disorder (n = 6), and bipolar II disorder (n = 22)." | 1.46 | Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder. ( Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Suzuki, T, 2017) |
| " This was an open-label trial with a flexible dosing regimen." | 1.35 | Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: efficacy and tolerability. ( Cvetić, T; Damjanović, A; Ivković, M; Jasović-Gasić, M; Jovanović, A, 2009) |
| "Lamotrigine is an anticonvulsant with antidepressant properties, and reported effectiveness in bipolar depression." | 1.34 | Lamotrigine in the treatment of recurrent brief depression. ( Ravindran, AV; Ravindran, LN, 2007) |
| "Lamotrigine has been shown in randomized controlled studies to be efficacious in preventing bipolar depression and rapid cycling states." | 1.33 | Sustained remission with lamotrigine augmentation or monotherapy in female resistant depressives with mixed cyclothymic-dysthymic temperament. ( Connor, PD; Cunningham, PD; Haykal, RF; Jackson, WC; Long, S; Manning, JS, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (54.76) | 29.6817 |
| 2010's | 13 (30.95) | 24.3611 |
| 2020's | 6 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Matsuzaka, Y | 1 |
| Urashima, K | 1 |
| Sakai, S | 1 |
| Morimoto, Y | 1 |
| Kanegae, S | 1 |
| Kinoshita, H | 1 |
| Imamura, A | 1 |
| Ozawa, H | 1 |
| Suwarno, S | 1 |
| Vedula, S | 1 |
| Shah, N | 1 |
| Artounian, K | 1 |
| Petty, A | 1 |
| Kumar, R | 1 |
| Garzon, J | 1 |
| Yuruk, D | 1 |
| Hassett, LC | 1 |
| Saliba, M | 1 |
| Ozger, C | 1 |
| Oztosun, C | 1 |
| Ahern, K | 1 |
| Athreya, AP | 1 |
| Singh, B | 1 |
| Croarkin, PE | 1 |
| Vande Voort, JL | 1 |
| Costa, B | 1 |
| Vale, N | 1 |
| Zhou, JY | 1 |
| Martinez, JA | 1 |
| Shen, JP | 1 |
| Suzuki, T | 3 |
| Mihara, K | 4 |
| Nagai, G | 3 |
| Kagawa, S | 3 |
| Nakamura, A | 4 |
| Nemoto, K | 3 |
| Kondo, T | 4 |
| McIntyre, RS | 1 |
| Berk, M | 1 |
| Brietzke, E | 1 |
| Goldstein, BI | 1 |
| López-Jaramillo, C | 1 |
| Kessing, LV | 1 |
| Malhi, GS | 1 |
| Nierenberg, AA | 2 |
| Rosenblat, JD | 1 |
| Majeed, A | 1 |
| Vieta, E | 2 |
| Vinberg, M | 1 |
| Young, AH | 1 |
| Mansur, RB | 1 |
| Andrade, C | 1 |
| Jaffe, RJ | 2 |
| Juneja, NS | 2 |
| Coffey, BJ | 1 |
| Takács, R | 1 |
| Makkos, Z | 1 |
| Kassai-Farkas, Á | 1 |
| Pusztai, Á | 1 |
| Ungvári, GS | 1 |
| Gazdag, G | 1 |
| Shon, SH | 1 |
| Joo, Y | 1 |
| Lee, JS | 1 |
| Kim, HW | 1 |
| Solmi, M | 1 |
| Veronese, N | 1 |
| Zaninotto, L | 1 |
| van der Loos, ML | 2 |
| Gao, K | 1 |
| Schaffer, A | 1 |
| Reis, C | 1 |
| Normann, C | 2 |
| Anghelescu, IG | 2 |
| Correll, CU | 1 |
| Mulder, PG | 1 |
| Hartong, EG | 1 |
| Blom, MB | 1 |
| Vergouwen, AC | 1 |
| de Keyzer, HJ | 1 |
| Notten, PJ | 1 |
| Luteijn, ML | 1 |
| Timmermans, MA | 1 |
| Nolen, WA | 1 |
| Chuang, JY | 1 |
| Tzeng, NS | 1 |
| Ivković, M | 1 |
| Damjanović, A | 1 |
| Jovanović, A | 1 |
| Cvetić, T | 1 |
| Jasović-Gasić, M | 1 |
| Vigo, DV | 1 |
| Baldessarini, RJ | 1 |
| Kuba, T | 1 |
| Yakushi, T | 1 |
| Hotta, H | 1 |
| Kojima, M | 1 |
| Warren, ZE | 1 |
| Sanders, KB | 1 |
| Veenstra-VanderWeele, J | 1 |
| Barbee, JG | 1 |
| Thompson, TR | 1 |
| Jamhour, NJ | 1 |
| Stewart, JW | 1 |
| Conrad, EJ | 1 |
| Reimherr, FW | 1 |
| Thompson, PM | 1 |
| Shelton, RC | 1 |
| Sachs, GS | 3 |
| Ice, KS | 1 |
| Chappell, PB | 1 |
| Schwartz, JH | 1 |
| Gurtovaya, O | 1 |
| Vanderburg, DG | 1 |
| Kasuba, B | 1 |
| Nazer, LH | 1 |
| Shankar, G | 1 |
| Ali, BA | 1 |
| Al-Najjar, T | 1 |
| Calabrese, JR | 3 |
| Sullivan, JR | 1 |
| Bowden, CL | 1 |
| Suppes, T | 2 |
| Goldberg, JF | 1 |
| Shelton, MD | 1 |
| Goodwin, FK | 1 |
| Frye, MA | 1 |
| Kusumakar, V | 1 |
| Margolese, HC | 1 |
| Beauclair, L | 1 |
| Szkrumelak, N | 1 |
| Chouinard, G | 1 |
| Masters, KJ | 1 |
| Melonas, JM | 1 |
| McElroy, SL | 1 |
| Zarate, CA | 1 |
| Cookson, J | 1 |
| Huffman, RF | 1 |
| Greene, P | 1 |
| Ascher, J | 1 |
| Lieb, K | 1 |
| Walden, J | 1 |
| Grunze, H | 1 |
| Fiebich, BL | 1 |
| Berger, M | 1 |
| Manning, JS | 2 |
| Haykal, RF | 1 |
| Connor, PD | 1 |
| Cunningham, PD | 1 |
| Jackson, WC | 1 |
| Long, S | 1 |
| Vajda, FJ | 1 |
| Solinas, C | 1 |
| Gutierrez, RL | 1 |
| McKercher, RM | 1 |
| Galea, J | 1 |
| Jamison, KL | 1 |
| Kugaya, A | 1 |
| Sanacora, G | 1 |
| Ostacher, MJ | 1 |
| Ketter, TA | 1 |
| Marangell, LB | 1 |
| Miklowitz, DJ | 1 |
| Miyahara, S | 1 |
| Bauer, MS | 1 |
| Thase, ME | 1 |
| Wisniewski, SR | 1 |
| Gabriel, A | 1 |
| McIntyre, J | 1 |
| Moral, MA | 1 |
| Ravindran, LN | 1 |
| Ravindran, AV | 1 |
| Muzina, DJ | 1 |
| Colangelo, E | 1 |
| Schindler, F | 1 |
| Selek, S | 1 |
| Savas, HA | 1 |
| da Rocha, FF | 1 |
| Soares, FM | 1 |
| Correa, H | 1 |
| Teixeira, AL | 1 |
| Derry, S | 1 |
| Moore, RA | 1 |
| Sagud, M | 1 |
| Pivac, N | 1 |
| Mustapic, M | 1 |
| Nedic, G | 1 |
| Peles, AM | 1 |
| Kramaric, M | 1 |
| Jakovljevic, M | 1 |
| Muck-Seler, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| A Mulitcentre, Double-blind, Randomised, Fixed-dose Evaluation of the Safety and Efficacy of Lamictal (Lamotrigine) Compared to Placebo as an add-on Therapy to Lithium or Another Mood Stabiliser in the Treatment of Bipolar Depression, Followed by Long-ter[NCT00224510] | Phase 3 | 120 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| A Preliminary Study of the Efficacy and Safety of Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency[NCT01379469] | Phase 2 | 20 participants (Actual) | Interventional | 2012-01-31 | Terminated | ||
| Lamotrigine as an Antidepressant Augmentation Agent in Treatment Refractory Unipolar Depression[NCT00901407] | 138 participants (Actual) | Interventional | 2003-12-31 | Completed | |||
| A Six-Week, Double-Blind, Multicenter, Placebo Controlled Study Evaluating The Efficacy And Safety Of Flexible Doses Of Oral Ziprasidone As Add-On, Adjunctive Therapy With Lithium, Valproate Or Lamotrigine In Bipolar I Depression[NCT00483548] | Phase 3 | 298 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)[NCT00012558] | 5,000 participants | Interventional | 1998-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CGI-S is a single-item clinician rated scale used to assess global severity of bipolar illness based on an overall evaluation of symptoms of bipolar mania, associated behavioral symptoms, and condition of the subject. Scored from 1 (normal, not at all ill) to 7 (among the most severely ill subjects). Higher score = more affected. Change calculated as a difference between post-baseline observation and baseline CGI-S score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) |
|---|---|
| Ziprasidone | -1.5 |
| Placebo | -1.5 |
MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts); rated on a 7-point Likert scale 0 (normal) to 6 (most abnormal); total score 0 to 44 (higher score indicates greater severity of symptoms). Change calculated as a difference between post-baseline observation and baseline MADRS score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) |
|---|---|
| Ziprasidone | -14.7 |
| Placebo | -13.2 |
Number of subjects with improvement defined as CGI-I response of 1 (very much improved) or 2 (much improved). CGI-I is a single-item clinician rated scale used to assess global improvement in the subject's clinical state (bipolar mania) in response to study treatment and as compared to their status at pre-treatment baseline. Scores range from 1 (very much improved) to 4 (no change) to 7 (very much worse). Higher score = more affected. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | participants (Number) |
|---|---|
| Ziprasidone | 66 |
| Placebo | 69 |
Number of subjects with MADRS total score ≤ 12 (indicates remission). MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts); rated on a 7-point Likert scale 0 (normal) to 6 (most abnormal); total score 0 to 44 (higher score indicates greater severity of symptoms). (NCT00483548)
Timeframe: Week 6
| Intervention | participants (Number) |
|---|---|
| Ziprasidone | 48 |
| Placebo | 54 |
Number of subjects with reduction of ≥50 percent (%) in MADRS total score (indicates response). MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts); rated on a 7-point Likert scale 0 (normal) to 6 (most abnormal); total score 0 to 44 (higher score indicates greater severity of symptoms). Reduction calculated as ([A-B]/B*100): A=value at observation; B=baseline value. (NCT00483548)
Timeframe: Week 6
| Intervention | participants (Number) |
|---|---|
| Ziprasidone | 62 |
| Placebo | 65 |
CGI-I is a single-item clinician rated scale used to assess global improvement in the subject's clinical state (bipolar mania) in response to study treatment and as compared to their status at pre-treatment baseline. Scores range from 1 (very much improved) to 4 (no change) to 7 (very much worse). Higher score = more affected. Week 6 is the primary timepoint. (NCT00483548)
Timeframe: Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
| Intervention | scores on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 1 (n=142, 141) | Week 2 (n=120, 138) | Week 3 (n=115, 130) | Week 4 (n=106, 122) | Week 5 (n=103, 112) | Week 6 (n=92, 108) | |
| Placebo | 3.4 | 3.1 | 2.9 | 2.8 | 2.6 | 2.4 |
| Ziprasidone | 3.2 | 2.9 | 2.7 | 2.6 | 2.5 | 2.4 |
AIMS is a clinician rated 12-item scale to rate 7 body areas and global judgments on the severity of abnormal movements, incapacitation and subject's awareness of abnormal movements. Items 1 to 10 scored 0 (none) to 4 (severe); items 11 to 14 are No or Yes response to dental status and sleep movements and are assessed separately. AIMS total score is sum of first 7 items. Change calculated as a difference between post-baseline observation and baseline AIMS score values. (NCT00483548)
Timeframe: Baseline, Week 2, Week 4, Week 6
| Intervention | scores on scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total score: Week 2 (n=136, 142) | Total score: Week 4 (n=111, 127) | Total score: Week 6 (n=100, 111) | Global severity score: Week 2 (n=136, 142) | Global severity score: Week 4 (n=111, 127) | Global severity score: Week 6 (n=100, 111) | Incapacitation score: Week 2 (n=136, 142) | Incapacitation score: Week 4 (n=111, 127) | Incapacitation score: Week 6 (n=100, 111) | |
| Placebo | -0.1 | -0.0 | -0.0 | -0.0 | 0.0 | 0.0 | -0.0 | -0.0 | 0.0 |
| Ziprasidone | 0.1 | -0.0 | -0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
BARS is a clinician rated scale to evaluate akathisia associated with use of antipsychotic medications: objective motor restlessness, range 0 to 3; subjective complaints of restlessness and associated distress, range 0 to 3; global clinical assessment of akathisia, range 0 to 5. Higher scores indicate more affected. Change calculated as a difference between post-baseline observation and baseline BARS score values. (NCT00483548)
Timeframe: Baseline, Week 2, Week 4, Week 6
| Intervention | scores on scale (Mean) | ||
|---|---|---|---|
| Week 2 (n=135, 139) | Week 4 (n=111, 125) | Week 6 (n=100, 110) | |
| Placebo | -0.0 | 0.0 | -0.0 |
| Ziprasidone | 0.1 | 0.0 | 0.0 |
CGI-S is a single-item clinician rated scale used to assess global severity of bipolar illness based on an overall evaluation of symptoms of bipolar mania, associated behavioral symptoms, and condition of the subject. Scores range from 1 (normal, not at all ill) to 7 (among the most severely ill subjects). Higher score = more affected. Change calculated as a difference between post-baseline observation and baseline CGI-S score values. (NCT00483548)
Timeframe: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5
| Intervention | scores on scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 1 (n=142, 141) | Week 2 (n=120, 139) | Week 3 (n=115, 130) | Week 4 (n=106, 122) | Week 5 (n=103, 112) | |
| Placebo | -0.4 | -0.7 | -0.9 | -1.1 | -1.3 |
| Ziprasidone | -0.5 | -0.9 | -0.9 | -1.1 | -1.3 |
GAF is a clinician rated scale to measure the severity of illness-related impairment in psychological, social, and occupational functioning using a 100-point scale (single score of 1 to 100) with 100 indicating a superior level of function. Change calculated as a difference between post-baseline observation and baseline GAF score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) | |
|---|---|---|
| Week 6 (n=100, 110) | ET (n=34, 27) | |
| Placebo | 11.2 | 2.8 |
| Ziprasidone | 14.7 | 0.0 |
HAM-A is a clinician rated 14-item scale that rates the intensity of psychic anxiety (items 1 to 6 and item 14) and somatic anxiety (items 7 to 13) on a 5-point severity scale; scores range from 0 (not present) to 4 (very severe); lower score indicates less affected. Change calculated as a difference between post-baseline observation and baseline HAM-A score values. Week 6 is the primary timepoint. (NCT00483548)
Timeframe: Baseline, Week 2, Week 4, Week 6
| Intervention | scores on scale (Mean) | ||
|---|---|---|---|
| Week 2 (n=136, 141) | Week 4 (n=111, 127) | Week 6 (n=100, 111) | |
| Placebo | -5.9 | -7.4 | -8.6 |
| Ziprasidone | -5.6 | -7.1 | -8.5 |
MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts); rated on a 7-point Likert scale 0 (normal) to 6 (most abnormal); total score 0 to 44 (higher score indicates greater severity of symptoms). Change calculated as a difference between post-baseline observation and baseline MADRS score values. (NCT00483548)
Timeframe: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5
| Intervention | scores on scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 1 (n=142, 141) | Week 2 (n=121, 139) | Week 3 (n=115, 130) | Week 4 (n=106, 122) | Week 5 (n=103, 112) | |
| Placebo | -6.1 | -9.0 | -11.0 | -11.8 | -13.3 |
| Ziprasidone | -8.1 | -11.7 | -13.0 | -14.1 | -14.9 |
Q-LES-Q is a 16-item subject rated scale to measure satisfaction with areas of daily functioning (physical health, social relationships, medication, and overall life satisfaction); rated on a 5-point Likert scale: higher scores indicate greater enjoyment and satisfaction with general life activities. Scores for items 1 to 14 are summed for a total score and converted to 0 to 100 range. Items 15 and 16 measure satisfaction with medication and overall satisfaction and are analyzed separately. Change calculated as a difference between post-baseline observation and baseline Q-LES-Q score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Total Q-LES-Q: Week 6 (n=82, 94) | Total Q-LES-Q: ET (n=27, 17) | Medications: Week 6 (n=91, 93) | Medications: ET (n=27, 20) | Overall life satisfaction: Week 6 (n=94, 103) | Overall life satisfaction: ET (n=31, 23) | |
| Placebo | 11.6 | 1.6 | 0.3 | -0.4 | 0.5 | 0.0 |
| Ziprasidone | 15.2 | -0.1 | 0.4 | -0.3 | 0.8 | 0.1 |
SDS is a 5-item subject rated scale to measure the extent to which work and or school, social life and or leisure activities, and home life and or family responsibilities were impaired by psychiatric illness. Items 1 to 3 rated on 11-point scale ranging 0 (not at all) to 10 (extremely affected). Total score 0 to 30; higher score indicates greater impairment; items 4 and 5 report number of days in the last month (0 to 31) subject missed work or school or was unproductive and are rated separately. Change calculated as a difference between post-baseline observation and baseline SDS score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Total SDS: Week 6 (n=58, 63) | Total SDS: ET (n=19, 14) | Work/School: Week 6 (n=58, 64) | Work/School: ET (n=19, 14) | Social life: Week 6 (n=94, 102) | Social life: ET (n=31, 23) | Family/Home: Week 6 (n=94, 102) | Family/Home: ET (n=31, 23) | |
| Placebo | -3.7 | -1.4 | -1.6 | -0.1 | -1.7 | 0.1 | -1.7 | -0.6 |
| Ziprasidone | -8.5 | 0.2 | -2.1 | 0.4 | -2.5 | -0.5 | -2.6 | 0.2 |
SDS is a 5-item subject rated scale to measure the extent to which work and or school, social life and or leisure activities, and home life and or family responsibilities were impaired by psychiatric illness. Items 1 to 3 rated on 11-point scale ranging 0 (not at all) to 10 (extremely affected). Total score 0 to 30; higher score indicates greater impairment; items 4 and 5 report number of days in the last month (0 to 31) subject missed work or school or was unproductive and are rated separately. Change calculated as a difference between post-baseline observation and baseline SDS score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | days (Mean) | |||
|---|---|---|---|---|
| Days lost: Week 6 (n=85, 93) | Days lost: ET (n=29, 21) | Days unproductive: Week 6 (n=87, 89) | Days unproductive: ET (n=29, 21) | |
| Placebo | -0.7 | 0.0 | -1.3 | -0.1 |
| Ziprasidone | -1.2 | 0.5 | -1.6 | -0.2 |
SAS is a clinician rated 10-item scale to measure extrapyramidal side effects (Parkinsonism or Parkinsonian side effects induced with antipsychotics); rated on a 5-point scale with range 0 (absence of condition) to 4 (presence of condition in extreme form). Global score is sum of all scores divided by the total number of items. Change calculated as a difference between post-baseline observation and baseline SAS score values. (NCT00483548)
Timeframe: Baseline, Week 2, Week 4, Week 6
| Intervention | scores on scale (Mean) | ||
|---|---|---|---|
| Week 2 (n=136, 141) | Week 4 (n=111, 126) | Week 6 (n=100, 110) | |
| Placebo | -0.1 | 0.0 | -0.1 |
| Ziprasidone | 0.1 | 0.0 | 0.0 |
YMRS is clinician rated 11-item scale (elevated mood, increased motor activity-energy, sexual interest, sleep, irritability, speech [rate and amount], language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight) used to assess the severity of manic symptoms and effect of treatment on mania severity. Seven items ranked on scale from 0 to 4; 4 items ranked 0 to 8. Higher scores indicate greater severity. Change calculated as a difference between post-baseline observation and baseline YMRS score values. Week 6 is the primary timepoint. (NCT00483548)
Timeframe: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
| Intervention | scores on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 1 (n=142, 141) | Week 2 (n=121, 139) | Week 3 (n=115, 130) | Week 4 (n=106, 122) | Week 5 (n=103, 112) | Week 6 (n=92, 108) | |
| Placebo | -0.2 | -0.2 | -0.2 | -1.1 | -1.3 | -0.9 |
| Ziprasidone | 0.7 | 0.5 | -0.0 | -0.9 | -0.9 | -1.0 |
13 reviews available for lamotrigine and Depression, Involutional
| Article | Year |
|---|---|
Efficacy and safety of lamotrigine in pediatric mood disorders: A systematic review.
Topics: Adolescent; Bipolar Disorder; Child; Depressive Disorder, Major; Humans; Lamotrigine; Triazines | 2023 |
Understanding Lamotrigine's Role in the CNS and Possible Future Evolution.
Topics: Anticonvulsants; Central Nervous System; Depressive Disorder, Major; Epilepsy; Glutamic Acid; Humans | 2023 |
Bipolar disorders.
Topics: Adolescent; Adult; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; B | 2020 |
Ketamine for Depression, 5: Potential Pharmacokinetic and Pharmacodynamic Drug Interactions.
Topics: Antidepressive Agents; Benzodiazepines; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Depressive | 2017 |
Lamotrigine in the treatment of psychotic depression associated with hereditary coproporphyria -- case report and a brief review of the literature.
Topics: Adult; Antipsychotic Agents; Coproporphyria, Hereditary; Depressive Disorder, Major; Female; Humans; | 2014 |
Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
Topics: Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bip | 2016 |
Sjögren's syndrome precipitated by lamotrigine treatment.
Topics: Depressive Disorder, Major; Female; Humans; Lamotrigine; Middle Aged; Sjogren's Syndrome; Treatment | 2009 |
Anticonvulsants in the treatment of major depressive disorder: an overview.
Topics: Anticonvulsants; Antidepressive Agents; Carbamazepine; Clinical Trials as Topic; Depressive Disorder | 2009 |
Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Cross-Sectional Studies; Depressive Disorder, M | 2002 |
Beyond monoamines: glutamatergic function in mood disorders.
Topics: Bipolar Disorder; Brain; Clinical Trials as Topic; Depressive Disorder, Major; Excitatory Amino Acid | 2005 |
Spotlight on lamotrigine for depression.
Topics: Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Drug Resistance; Drug T | 2006 |
Differentiating bipolar disorder from depression in primary care.
Topics: Bipolar Disorder; Depression; Depressive Disorder, Major; Diagnosis, Differential; Humans; Lamotrigi | 2007 |
Atypical antipsychotics in bipolar disorder: systematic review of randomised trials.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Bipolar Disorder; Depressive Disorder | 2007 |
8 trials available for lamotrigine and Depression, Involutional
| Article | Year |
|---|---|
Prediction of an Optimal Dose of Lamotrigine for Augmentation Therapy in Treatment-Resistant Depressive Disorder From Plasma Lamotrigine Concentration at Week 2.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Chromatograp | 2016 |
Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Depressive Disorder, Major; Dose-Respons | 2009 |
A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Depres | 2011 |
Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antimanic Agents; Bipolar Disorder; Depressive Disorder, Maj | 2011 |
A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Relationship, Dr | 2004 |
Serum levels of substance P and response to antidepressant pharmacotherapy.
Topics: Acute Disease; Adult; Antidepressive Agents; Depressive Disorder, Major; Humans; Lamotrigine; Paroxe | 2004 |
Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Depressive Di | 2006 |
Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Depressive Disorder, Major; Drug Re | 2007 |
21 other studies available for lamotrigine and Depression, Involutional
| Article | Year |
|---|---|
The effectiveness of lamotrigine for persistent depressive disorder: A case report.
Topics: Antidepressive Agents; Anxiety Disorders; Depressive Disorder, Major; Female; Humans; Lamotrigine; S | 2022 |
Lamotrigine-Induced Persistent Genital Arousal Disorder and a Potential Treatment.
Topics: Arousal; Depressive Disorder, Major; Female; Genitalia; Humans; Lamotrigine; Sexual Dysfunction, Phy | 2023 |
Lamotrigine-induced hemophagocytic lymphohistiocytosis with Takotsubo cardiomyopathy: a case report.
Topics: Antipsychotic Agents; Anxiety Disorders; Bone Marrow; Depressive Disorder, Major; Dexamethasone; Fem | 2019 |
A High Plasma Lamotrigine Concentration at Week 2 as a Risk Factor for Lamotrigine-Related Rash.
Topics: Antipsychotic Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Exanthem | 2020 |
Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Depressive Disord | 2017 |
Fourteen-Pound Fluvoxamine-Associated Weight Gain in a Young Woman with Depression and Multiple Anxiety Symptoms.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety | 2018 |
Lamotrigine treatment of adolescents with unipolar and bipolar depression: a retrospective chart review.
Topics: Adolescent; Anticonvulsants; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Relationshi | 2014 |
Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: efficacy and tolerability.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationshi | 2009 |
Ropinirole augmentation therapy in a case with treatment-resistant unipolar depression.
Topics: Aged; Antidepressive Agents; Clomipramine; Depressive Disorder, Major; Dopamine Agonists; Drug Thera | 2010 |
Identity crisis involving body image in a young man with autism.
Topics: Adolescent; Anticonvulsants; Anxiety Disorders; Autistic Disorder; Behavior Therapy; Body Dysmorphic | 2010 |
Fatal agranulocytosis associated with psychotropic medication use.
Topics: Adult; Agranulocytosis; Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Ag | 2012 |
Hypomania induced by adjunctive lamotrigine.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Bupropion; Depressive Disorder, Major; Dose-Response | 2003 |
Lamotrigine and informed consent.
Topics: Antimanic Agents; Child; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Informed Cons | 2004 |
Sustained remission with lamotrigine augmentation or monotherapy in female resistant depressives with mixed cyclothymic-dysthymic temperament.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Cyclothymic Disorder; Depressive Disorder, Major; Di | 2005 |
Potential risks associated with high-dose valproate in pregnancy in psychiatric patients.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Relationship, D | 2005 |
Lamotrigine augmentation strategy for patients with treatment-resistant depression.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Depressive Disorder, Major; Drug Resistance; Drug The | 2005 |
Lamotrigine adjunctive treatment in resistant unipolar depression: an open, descriptive study.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Depressive Disorder, Major; Drug Resistance; Drug The | 2006 |
Lamotrigine in the treatment of recurrent brief depression.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Depressive Disorder, Major; Humans; Lamotrigine; Male | 2007 |
Lamotrigine-induced manic switches have already been reported.
Topics: Antimanic Agents; Bipolar Disorder; Depressive Disorder, Major; Humans; Lamotrigine; Triazines | 2007 |
Addition of lamotrigine to valproic acid: a successful outcome in a case of rapid-cycling bipolar affective disorder.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Depressive Disorder, Major; Female; Humans; Lamotrigine; | 2007 |
The effect of lamotrigine on platelet serotonin concentration in patients with bipolar depression.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bipolar Diso | 2008 |